positive phase II results in cancer pain announced 11/09; EU approval expected 2Q10 for MS spasticity; positive phase IIb results prompts continuation to phase III in cancer pain (3/10); approved in UK 6/10 for spasticity in MS
Brand Sativex Generic CBD (cannabidiol) and THC (delta 9 tetrahydrocannabinol)
Company name GW, Otsuka Product type Non-speciality
Therapeutic category CNS Key uses Cancer pain, spasticity in multiple sclerosis (MS)
Other Uses neuropathic pain, neuropathic pain in multiple sclerosis (MS) Drug Class cannabinoid
Dosage From oral spray Expected Approval 2012+
FDA Filing N/A Last Update date June 22,2010
Link to pipeline report
Link to news article
Link to press releases